Q4, 2019, 2020 Earnings Estimates for Pacira Biosciences Raised
3:06AM ET 11/09/2019 MT NewswiresConsensus estimates for Q4 ending December 31, 2019, and the full year forecasts for 2019 and 2020 for the years ending on December 31 for Pacira...
Consensus estimates for Q4 ending December 31, 2019, and the full year forecasts for 2019 and 2020 for the years ending on December 31 for Pacira...
The full year forecasted earnings estimates for 2019 and 2020 for Pacira Biosciences Inc (NASDAQ:PCRX, Recent Price: 42.62) have been changed. The...
Pacira BioSciences (PCRX) on Thursday reported Q3 non-GAAP EPS of $0.48, compared with $0.31 a year earlier and the Capital IQ consensus forecast of $0.33....
Pacira Pharmaceuticals' (PCRX) average rating among analysts is a hold, with an average price target of $54. Price: 43.30, Change: +1.08, Percent Change:...
Address | 5 Sylvan Way Parsippany, New Jersey 07054 |
Phone | +1.973.254.3560 |
Number of Employees | 518 |
Recent SEC Filing | 12/06/2019![]() |
Chairman, Chief Executive & Operating Officer | David M. Stack |
President | Max Reinhardt |
Chief Financial Officer | Charles A. Reinhart |
Vice President-Research & Development | Vladimir Kharitonov |
Price Open | $45.65 |
Previous Close | $45.87 |
52 Week Range | $34.64 - 49.50 |
Market Capitalization | $1.9 B |
Shares Outstanding | 41.7 M |
Sector | Health Technology |
Industry | Pharmaceuticals: Other | Next Earnings Announcement | 02/27/2020 |
Call Open Interest (1d)* | ![]() |
Put Open Interest (1d)* | ![]() |
Call Volume (1d)* | ![]() |
Put Volume (1d)* | ![]() |
Put Call Open Interest Ratio (1d)* | ![]() |
Put Call Volume Ratio (1d)* | ![]() |
* Data delayed by up to 15 minutes |
Price / Earnings | 1.1K |
Earnings per Share | $0.32 |
Beta vs. S&P 500 | N/A |
Revenue | $337.3 M |
Net Profit Margin | 0.55% |
Return on Equity | 0.65% |
Buy | |
Overweight | |
Hold | |
Underweight | |
Sell | |
Consensus Recommendation![]() |